FDA Upgrades Recall for Glenmark Pharmaceuticals Medications Affecting Over 112,000 Bottles

The U.S. Food and Drug Administration (FDA) has upgraded a recall for several commonly prescribed medications manufactured by Glenmark Pharmaceuticals Inc., impacting more than 112,000 bottles. The recall stems from manufacturing deviations that could compromise the safety and effectiveness of the medications. Affected products include specific lots of Propafenone Hydrochloride extended-release capsules 325 mg, Solifenacin Succinate tablets 10 mg, and Voriconazole tablets 200 mg. Patients currently using these recalled medications are advised to continue their treatment and consult their pharmacist, physician, or medical provider to discuss alternative options.